论文部分内容阅读
白细胞移动抑制试验(LMIT)与白细胞粘附抑制试验均曾用于研究黑色素瘤、乳房癌及结肠癌的肿瘤相关抗原,但尚未有报导用于胃癌中。本文介绍用LMIT研究针对胃癌相关抗原的细胞免疫。采用改良Reisfeld的3MKCl提取法从4例正常胃粘膜与10例胃癌切除标本中制备抗原。通过与正常人白细胞作用,确定最适抗原浓度为0.25mg/ml,白细胞移动指数(MI)的计算公式为 MI=(用抗原刺激的移动范围直径)/(无抗原刺激的移动范围直径) 测定10例正常人的MI后,确定正常范围为0.78～1.19,低于或高于此范围均作为病理性,表明由两种不同的淋巴因子作用而引起白细胞反应抑制或促进。
Both the leukocyte migration inhibition test (LMIT) and the leukocyte adhesion inhibition test have been used to study tumor-associated antigens of melanoma, breast cancer, and colon cancer, but they have not been reported for gastric cancer. This article describes the use of LMIT to study cellular immunity against gastric cancer-associated antigens. Antigens were prepared from 4 cases of normal gastric mucosa and 10 cases of gastric cancer resection specimens using the modified Reisfeld 3MKCl extraction method. By interacting with normal human leukocytes, the optimal antigen concentration was determined to be 0.25 mg/ml, and the calculation formula for the leukocyte migration index (MI) was MI=(diameter of moving range stimulated with antigen)/(diameter of moving range without antigen stimulation) After the MI of 10 normal subjects, the normal range was 0.78 to 1.19. Lower or higher than this range was considered pathological, suggesting that the effects of two different lymphokines cause inhibition or promotion of leukocyte responses.